查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1592899

小兒驚厥治療藥物市場：依劑量、給藥途徑- 全球預測 2025-2030 年

Infantile Spasms Therapeutics Market by Dosage (Liquid, Solid), Route of Administration (Oral, Parental) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年小兒驚厥治療市場價值為3.8175億美元，預計到2024年將達到4.0601億美元，複合年成長率為6.44%，預計到2030年將達到5.9124億美元。

兒科癲癇治療市場包括開發、生產和分銷用於管理和緩解兒科癲癇症狀的治療方法，兒科癲癇是一種影響嬰幼兒和幼兒的罕見神經系統疾病。這個市場包括旨在改善患者預後的藥物、飲食療法和手術干預。對這些療法的需求源於解決與未經治療的癲癇發作相關的發育遲緩和神經缺陷的迫切需求。典型應用包括抗癲癇藥物、荷爾蒙療法和生酮飲食管理，最終用戶包括醫院、診所和專業醫學研究中心。該市場的主要成長要素是人們對該疾病的認知不斷提高以及醫療診斷和影像技術的進步。對罕見疾病的監管激勵措施和增加對兒科神經病學研究的投資正在進一步支持市場成長。新的商機在於最佳化基因治療、探索生物製藥解決方案以及利用人工智慧進行早期準確診斷。公司可以透過加強研發力度、建立策略合作夥伴關係以及創新治療方法來抓住這些機遇，以滿足未滿足的需求。然而，該市場面臨著治療成本高、由於疾病稀有而導致患者數量有限以及嚴格的監管障礙等挑戰。提高我們對兒童癲癇發作遺傳基礎的理解並投資精準醫療可能是一個有希望的創新領域。專注於開發針對特定症狀的治療方法和整合遠端醫療解決方案以進行持續監控的公司將獲得顯著的成長和差異化。這個市場的性質是高度專業化的，由尖端研究和開發驅動，需要在臨床試驗和監管合規方面進行大量投資。然而，專注於策略夥伴關係和技術進步可以釋放這一利基治療領域的巨大潛力。

主要市場統計
基準年[2023] 38175萬美元
預測年份 [2024] 40601萬美元
預測年份 [2030] 5.9124 億美元
複合年成長率（%） 6.44%

市場動態：快速發展的兒科癲癇藥物市場的關鍵市場洞察

供需的動態交互作用正在改變兒科癲癇藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 中樞神經系統 (CNS)感染疾病盛行率增加
    • 兒童癲癇藥物的使用率不斷增加
    • 政府和私人組織提高意識以減少未確診病例的數量
  • 市場限制因素
    • 兒童驚厥的治療費用不斷上升且缺乏正確的診斷
  • 市場機會
    • 擴大兒科癲癇治療的科學進展
    • 增加廣泛的研發活動
  • 市場挑戰
    • 藥品核准嚴格規定

波特五力：駕馭兒科癲癇藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解小兒驚厥治療市場的外在影響

外部宏觀環境因素在塑造小兒驚厥治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解小兒驚厥治療藥物市場的競爭狀況

對小兒驚厥治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣小兒驚厥治療藥物市場供應商的績效評估

FPNV 定位矩陣是評估小兒驚厥治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃小兒驚厥治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對小兒驚厥治療藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 中樞神經系統 (CNS)感染疾病盛行率增加
      • 癲癇藥物的普及率不斷上升
      • 政府和私人組織為減少未確診病例數而進行的宣傳活動
    • 抑制因素
      • 癲癇治療費用高且缺乏適當的診斷
    • 機會
      • 擴大癲癇治療的科學進步
      • 擴大廣泛的研究和開發活動
    • 任務
      • 藥品核准嚴格規定
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章小兒驚厥治療藥物市場按劑量

  • 液體
  • 固體的

第7章小兒驚厥治療藥物市場：依途徑

  • 口服
  • 監護人

第8章北美和南美小兒癲癇治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區小兒驚厥治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲小兒驚厥治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Anavex Life Sciences Corp.
  • Cerecin Inc.
  • H. Lundbeck A/S
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • MSN Laboratories Private Limited
  • ORPHELIA Pharma
  • Ovid Therapeutics Inc.
  • Zydus Group
Product Code: MRR-43127F727967

The Infantile Spasms Therapeutics Market was valued at USD 381.75 million in 2023, expected to reach USD 406.01 million in 2024, and is projected to grow at a CAGR of 6.44%, to USD 591.24 million by 2030.

The scope of the Infantile Spasms Therapeutics market entails the development, production, and distribution of treatments designed to manage and alleviate symptoms of infantile spasms, a rare neurological disorder affecting infants. It involves pharmaceuticals, dietary treatments, and surgical interventions aimed at improving patient outcomes. The necessity of these therapeutics stems from the critical need to address developmental delays and neurological deficits associated with untreated spasms. Key applications include antiepileptic drugs, hormone therapy, and ketogenic diet management, with end-users encompassing hospitals, clinics, and specialized medical research centers. A major growth factor in this market is the increasing awareness of the disorder and advancements in medical diagnostics and imaging technologies. Regulatory incentives for rare diseases and the rising investment in pediatric neurology research further propel market growth. Emerging opportunities lie in optimizing gene therapy, exploring biopharmaceutical solutions, and leveraging AI for early and precise diagnosis. Businesses can capture these opportunities by intensifying R&D efforts, forging strategic collaborations, and addressing unmet needs with innovation in treatment delivery. However, the market faces challenges such as high costs of treatment, limited patient pool due to the rarity of the condition, and stringent regulatory hurdles. Nurturing an understanding of the genetic basis of infantile spasms and investing in precision medicine can be promising areas of innovation. Companies focusing on developing symptom-specific therapies and integrating telehealth solutions for continued monitoring could realize substantial growth and differentiation. The nature of the market is highly specialized, driven by cutting-edge research and development, and it demands significant investment in clinical trials and regulatory compliance. Nonetheless, with an emphasis on strategic partnerships and technological advancements, businesses can unlock substantial potential within this niche therapeutic arena.

KEY MARKET STATISTICS
Base Year [2023] USD 381.75 million
Estimated Year [2024] USD 406.01 million
Forecast Year [2030] USD 591.24 million
CAGR (%) 6.44%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infantile Spasms Therapeutics Market

The Infantile Spasms Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of central nervous system (CNS) infection
    • Rising penetration rate of infantile spasm drugs
    • Awareness by government and private organizations to decrease the number of undiagnosed cases
  • Market Restraints
    • High cost of treatment and lack of proper diagnosis of infantile spasm
  • Market Opportunities
    • Expanding scientific advancements in the treatment for infantile spasms
    • Increasing extensive research and development activities
  • Market Challenges
    • Stringent regulations for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Infantile Spasms Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infantile Spasms Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infantile Spasms Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infantile Spasms Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infantile Spasms Therapeutics Market

A detailed market share analysis in the Infantile Spasms Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infantile Spasms Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infantile Spasms Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Infantile Spasms Therapeutics Market

A strategic analysis of the Infantile Spasms Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Infantile Spasms Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Anavex Life Sciences Corp., Cerecin Inc., H. Lundbeck A/S, Lupin Limited, Mallinckrodt Pharmaceuticals, MSN Laboratories Private Limited, ORPHELIA Pharma, Ovid Therapeutics Inc., and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Infantile Spasms Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Dosage, market is studied across Liquid and Solid.
  • Based on Route of Administration, market is studied across Oral and Parental.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of central nervous system (CNS) infection
      • 5.1.1.2. Rising penetration rate of infantile spasm drugs
      • 5.1.1.3. Awareness by government and private organizations to decrease the number of undiagnosed cases
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and lack of proper diagnosis of infantile spasm
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding scientific advancements in the treatment for infantile spasms
      • 5.1.3.2. Increasing extensive research and development activities
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations for drug approval
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Infantile Spasms Therapeutics Market, by Dosage

  • 6.1. Introduction
  • 6.2. Liquid
  • 6.3. Solid

7. Infantile Spasms Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parental

8. Americas Infantile Spasms Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Infantile Spasms Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Infantile Spasms Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Anavex Life Sciences Corp.
  • 2. Cerecin Inc.
  • 3. H. Lundbeck A/S
  • 4. Lupin Limited
  • 5. Mallinckrodt Pharmaceuticals
  • 6. MSN Laboratories Private Limited
  • 7. ORPHELIA Pharma
  • 8. Ovid Therapeutics Inc.
  • 9. Zydus Group

LIST OF FIGURES

  • FIGURE 1. INFANTILE SPASMS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. INFANTILE SPASMS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. INFANTILE SPASMS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFANTILE SPASMS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFANTILE SPASMS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. INFANTILE SPASMS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. INFANTILE SPASMS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023